GERN Projected Dividend Yield

Geron Corp. ( NASDAQ : GERN )

Geron is a biopharmaceutical company that is focused on the development and commercialization of imetelstat, a telomerase inhibitor. Co. is conducting two ongoing Phase 3 clinical trials that are designed to enable registration of imetelstat: (i) IMerge Phase 3 in lower risk myelodysplastic syndromes (MDS), and (ii) IMpactMF in refractory myelofibrosis (MF). Imetelstat has been granted Fast Track designations by the U.S. Food and Drug Administration for the treatment of patients with transfusion-dependent anemia due to lower risk MDS and who are refractory or resistant to treatment with an erythropoiesis stimulating agent and for the treatment of patients with MF.

20 YEAR PERFORMANCE RESULTS